Video
Dr. Stephen Savage discusses molecular testing and unmet needs in prostate cancer
Author(s):
“We really try to be careful about testing, especially when it's a potential burden of costs on the patient. What we really look at is where it's going to have an impact,” says Stephen J. Savage, MD.
Video Player is loading.
In this interview, Stephen J. Savage, MD, discusses current research he’s working on, the role of molecular testing in prostate cancer as well as unmet needs in treating the disease. Savage is director of minimally invasive urology at the Medical University of South Carolina, Charleston.
Related Videos
Study results affirm effectiveness of evolving prostate cancer therapies
Laura Davis, MD, on link between microplastics and bladder cancer
Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
Considerations for patient follow-up after onabotA administration
Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
Administering onabotA: Improving patient comfort and easing anxiety
Expert discusses genitourinary syndrome of menopause guidelines
Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
Joshua Heiman, MD, on phentermine plus topiramate for uric acid stone prevention
Amy Krambeck, MD, on innovation and building strong programs in endourology
Related Content
